Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Assets

VLS-01

atai Therapeutics

Molecule class
DMT, buccal film formulation (acquirer release)
Mechanism
Not independently verified. See A001 note.
Phase
Phase 2b; last patient dosed 2026-07-06; Phase 3 in MDD planned
Indication
treatment-resistant depression; planned MDD
Sponsor geography
US
Next catalyst
Phase 3 initiation; CVR milestone one pays up to $1.00 per CVR if a Phase 3 of VLS-01 is initiated before the 4th anniversary of the 2026-09-11 Closing Date, by 2030-09-11
Partner
Eli Lilly and Company (acquisition closed 2026-09-11)
IP status
Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as reported, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

clinicaltrials.govregistryverified 2026-09-15

Registered trials

  • NCT06524830ClinicalTrials.gov

    PHASE2 · Treatment Resistant Depression · RECRUITING · Australia, Canada, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

Last financing

In the briefing

Issues tagged ATAI-THERAPEUTICS, the owner of this asset.